Gregory B. Lawless
Corporate Officer/Principal bei Collins Mabry & Co. LLC
Profil
Gregory B.
Lawless has been Managing Partner of Collins Mabry & Co. since 1998.
Previously, he was President and Chief Executive Officer of Cygnus, Inc. from 1992 to 1998 and President and Chief Operating Officer of Chiron Corporation from 1989 to 1992.
Dr. Lawless received a BS degree in Pharmacy from Fordham University, an MS degree in Analytical Chemistry from St. John's University and a PhD in Physical Organic Chemistry from Temple University.
Aktive Positionen von Gregory B. Lawless
| Unternehmen | Position | Beginn |
|---|---|---|
| Collins Mabry & Co. LLC | Corporate Officer/Principal | 01.01.1998 |
Ehemalige bekannte Positionen von Gregory B. Lawless
| Unternehmen | Position | Ende |
|---|---|---|
Vyteris, Inc.
 Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Direktor/Vorstandsmitglied | 06.02.2008 |
| ORASURE TECHNOLOGIES, INC. | Direktor/Vorstandsmitglied | 16.05.2005 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ORASURE TECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Vyteris, Inc.
Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Health Technology |
| Collins Mabry & Co. LLC |